GSK Will Pay Up To $3.3 Billion Acquiring Affinivax To Expand Its Vaccine Portfolio.
GSK agreed to buy Affinivax, a U.S. biotech, for up to $3.3 billion on Tuesday, its second large transaction in two months, giving the British pharmaceutical giant access to the company’s pipeline of next-generation vaccines. GSK, one of the world’s largest vaccine manufacturers, has been under pressure to strengthen its pharmaceutical pipeline ahead of the…









